Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasm, Residual × flumatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm, Residual 1

Interventions

osimertinib 1 obinutuzumab 1 midostaurin 1 flumatinib 1 fludarabine 1 Radiotherapy 1 Oxaliplatin 1 Mitoxantrone 1 Mercaptopurine 1 Leucovorin 1 Irinotecan 1 Gemtuzumab 1 Folfox protocol 1 Fluorouracil 1 Drug Therapy 1 Daunorubicin 1 Cytarabine 1 Cyclophosphamide 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04375683 2022-03-24

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Zhongda Hospital

Phase 3 Unknown

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡